Navigation Links
CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
Date:1/24/2008

Lawsuit claims companies knowingly misled consumers on the use of Zetia and

Vytorin.

NEWARK, N.J., Jan. 24 /PRNewswire/ -- Hagens Berman Sobol Shapiro filed a proposed class-action lawsuit against Merck (NYSE: MRK) and Schering-Plough (NYSE: SGP), manufacturers of Zetia and Vytorin alleging Merck and Schering-Plough violated state consumer protection laws arising from the sale and marketing of Zetia and Vytorin.

The suit was filed on Jan. 17, 2008 in the U.S. District Court in Newark, New Jersey.

Vytorin is the combination of Zetia and Zocor, a statin now available as a generic drug for about one-third of the cost.

The suit claims the companies have known since 2006 that the combination of drugs was no more effective than the generic version of Zocor in blocking the fatty arterial plaques that can cause heart attack and stroke, as it led consumers to believe.

Zetia is a brand-name prescription used to lower LDL levels by decreasing cholesterol absorption in the intestinal tract. Other cholesterol-lowering drugs known as statins work in the liver.

Zetia was developed by Schering-Plough and jointly marketed by Merck and Schering-Plough, as is Vytorin.

The companies promoted Zetia heavily, advertising that by adding it to statin treatment, patients could more effectively lower LDL cholesterol which they claim would, in turn, reduce plaque in patients' arteries.

But according to the complaint, the companies had prior information that refuted that claim.

On Jan. 14, 2008, Merck/Schering-Plough released the results of a drug trial intended to prove the claim and show a correlation between lowered LDL levels and fatty plaques in the arteries, which can cause heart attacks and strokes.

While the study once again showed that Vytorin lowered LDL cholesterol rates better than Zocor alone, it also showed that the fatty arterial plaques actually grew somewhat faster in patients taking Zetia along with Zocor than in those taking Zocor alone.

The suit also calls into question the timing of the study's release. According to published reports, the two-year drug trial concluded April 2006 but wasn't announced until Jan. 15, 2008. According to the complaint, Merck and Schering-Plough knew the results of the trials but delayed sharing the findings with patients and did not change its marketing approach.

Zetia and Vytorin account for combined sales of $1.1 billion during the fourth quarter of 2007. The agreement with Merck and Schering-Plough provided that the companies split profits roughly 50-50, depending on regions.

The suit seeks the return of money to purchasers of Vytorin and Zetia, which the study shows are no more effective than the generic form of Zocor. The lawsuit will not seek relief for personal injuries that anyone may allege resulted from taking Vytorin or Zetia.

Visit http://www.hbsslaw.com/zetia.htm to read a more comprehensive background document or view the complaint. You can also contact plaintiff's attorneys, Steve Berman or Craig Spiegel at 206-623-7292 or via e-mail at info@hbsslaw.com.

About Hagens Berman Sobol Shapiro

Hagens Berman Sobol Shapiro is based in Seattle with offices in Chicago, Cambridge, Los Angeles, Phoenix and San Francisco. Since 1993, it has developed a nationally recognized practice in class-action and complex litigation. Among recent successes, HBSS has negotiated a $300 million settlement in the DRAM memory antitrust litigation; a $340 million recovery on behalf of Enron employees; a $150 million settlement involving charges of illegally inflated charges for the drug Lupron, and served as co-counsel on the Visa/Mastercard litigation which resulted in a $3 billion settlement, the largest anti-trust settlement to date. HBSS served as counsel in a $850 million Washington Public Power Supply settlement and represented Washington and 12 other states against the tobacco industry that resulted in the largest settlement in history. For a complete listing of HBSS cases, visit http://www.hbsslaw.com.

CONTACTS:

Steve Berman (206) 623-7292

Hagens Berman Sobol Shapiro

Steve@hbsslaw.com

Mark Firmani (206) 443-9357

Firmani + Associates, Inc.

Mark@firmani.com


'/>"/>
SOURCE Hagens Berman Sobol Shapiro
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia
2. Hagens Berman Sobol Shapiro: Judge Orders Double Damages, Issues Stinging Rebuke in Average Wholesale Price Case
3. Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces
4. Accuro Healthcare Solutions, Inc. Files Registration Statement for Proposed Initial Public Offering
5. The Willie Gary Law Firm Files $1 Billion Lawsuit Against Durham County LME, Wake County LME, Five County LME, Mecklenberg County LME and Value Options, Inc. for Negligent and Intentional Misconduct Against Mental Health Agency
6. Wisconsin Physicians Service Insurance Corporation Files Suit Against Aurora Health Care and HealthEOS
7. Famed Attorney Willie Gary Files $10.6 Billion in Lawsuits against Big Tobacco Companies on Behalf of Florida Smokers and their Families
8. Cynosure Files Patent Infringement Lawsuit Against CoolTouch Inc.
9. GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder
10. Manor Care Files Motion with West Virginia Health Care Authority to Dissolve Stay and Issue an Immediate Ruling
11. Procter & Gamble Files Infringement Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... ... The StayWell Company and VUCA Health announced today ... foster behavior change and improve health literacy among patients. VUCA Health, which created and ... its video capability at StayWell booth 3443 during HiMSS. , The VUCA library ...
(Date:2/20/2017)... ... February 20, 2017 , ... Sensogram Technologies ... by for a visit this week at HIMSS 2017 Conference & Exhibition. The ... the globe. Sensogram will be featured in the conference’s Connected Health Experience section, ...
(Date:2/20/2017)... Sunapee, NH (PRWEB) , ... February 20, 2017 , ... ReportingMD, a Population Health Software ... rapid growth of the company. The new location will triple the size of the ... location for the town of Sunapee, NH. , “We are excited to expand ...
(Date:2/20/2017)... St. Petersburg, Fla. (PRWEB) , ... February 20, 2017 , ... ... of its research and education building. A topping out ceremony on Friday marked the ... , The building, set to open in Fall 2018, will serve as a center ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ... eye care providers and health plan partners, announced during the 2017 Annual ... success enhancing care coordination for diabetic patients and integrating eye care into ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)... , Feb. 19, 2017  nThrive™, an independent ... portfolio and thought leadership at the 2017 HIMSS ... category leader award from KLAS. nThrive ... focused on how market trends shape the holistic, ... a sophisticated, comprehensive Patient Access solution. The panel ...
(Date:2/18/2017)... 17, 2017   Parker Waichman LLP, ... rights of victims injured by medical devices, comments ... call for better reporting. Congress required hospitals to ... concerns involving power morcellators and duodenoscopes prompted the ... how hospitals report injuries and deaths related to ...
(Date:2/17/2017)... 17, 2017 Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, ... global ablation technologies market is expected to grow at a CAGR ... market is expected to grow at a CAGR of 9.5% from ... and $9.05bn in 2026. ... How this report will benefit you Read on to ...
Breaking Medicine Technology: